SE9904176D0 - New use - Google Patents

New use

Info

Publication number
SE9904176D0
SE9904176D0 SE9904176A SE9904176A SE9904176D0 SE 9904176 D0 SE9904176 D0 SE 9904176D0 SE 9904176 A SE9904176 A SE 9904176A SE 9904176 A SE9904176 A SE 9904176A SE 9904176 D0 SE9904176 D0 SE 9904176D0
Authority
SE
Sweden
Prior art keywords
new use
disorders
prophylaxis
enantiomers
therapy
Prior art date
Application number
SE9904176A
Other languages
English (en)
Swedish (sv)
Inventor
Michael Balestra
George Mullen
Eifion Phillips
Richard Schmiesing
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904176A priority Critical patent/SE9904176D0/xx
Publication of SE9904176D0 publication Critical patent/SE9904176D0/xx
Priority to ARP000105840A priority patent/AR031680A1/es
Priority to EEP200200251A priority patent/EE200200251A/xx
Priority to PL00355867A priority patent/PL355867A1/xx
Priority to UA2002065003A priority patent/UA74172C2/uk
Priority to DE60020994T priority patent/DE60020994T2/de
Priority to PCT/SE2000/002262 priority patent/WO2001036417A1/en
Priority to CN008184216A priority patent/CN1217943C/zh
Priority to CZ20021692A priority patent/CZ20021692A3/cs
Priority to MXPA02004911A priority patent/MXPA02004911A/es
Priority to EP00981994A priority patent/EP1233964B1/en
Priority to US10/130,635 priority patent/US6683090B1/en
Priority to HU0204245A priority patent/HUP0204245A3/hu
Priority to IL14937400A priority patent/IL149374A0/xx
Priority to AT00981994T priority patent/ATE298337T1/de
Priority to KR1020027006257A priority patent/KR20020058014A/ko
Priority to JP2001538906A priority patent/JP2003514818A/ja
Priority to DK00981994T priority patent/DK1233964T3/da
Priority to NZ518571A priority patent/NZ518571A/en
Priority to BR0015624-8A priority patent/BR0015624A/pt
Priority to SK677-2002A priority patent/SK6772002A3/sk
Priority to HK02109290.6A priority patent/HK1047743B/en
Priority to CA002389604A priority patent/CA2389604A1/en
Priority to ES00981994T priority patent/ES2242653T3/es
Priority to PT00981994T priority patent/PT1233964E/pt
Priority to AU19073/01A priority patent/AU784400B2/en
Priority to SI200030716T priority patent/SI1233964T1/xx
Priority to CO00087729A priority patent/CO5261607A1/es
Priority to ZA200203316A priority patent/ZA200203316B/xx
Priority to BG106680A priority patent/BG106680A/bg
Priority to NO20022289A priority patent/NO20022289L/no
Priority to IS6385A priority patent/IS6385A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9904176A 1999-11-18 1999-11-18 New use SE9904176D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use
ARP000105840A AR031680A1 (es) 1999-11-18 2000-11-06 Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
SI200030716T SI1233964T1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
AT00981994T ATE298337T1 (de) 1999-11-18 2000-11-16 Neue verwendung sowie neue n-azabicycloamid- verbindungen
DK00981994T DK1233964T3 (da) 1999-11-18 2000-11-16 Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
UA2002065003A UA74172C2 (uk) 1999-11-18 2000-11-16 ЗАСТОСУВАННЯ ПОХІДНИХ N-АЗАБІЦИКЛОАМІДУ ДЛЯ ЛІКУВАННЯ ЧИ ПРОФІЛАКТИКИ ПСИХОТИЧНИХ РОЗЛАДІВ, А ТАКОЖ СТАНІВ, КОЛИ КОРИСНОЮ Є СТИМУЛЯЦІЯ НІКОТИНОВОГО РЕЦЕПТОРА <font face="Symbol">a7</font>
DE60020994T DE60020994T2 (de) 1999-11-18 2000-11-16 Neue verwendung sowie neue n-azabicycloamid-verbindungen
PCT/SE2000/002262 WO2001036417A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
CN008184216A CN1217943C (zh) 1999-11-18 2000-11-16 新的用途和新的n－氮杂双环－酰胺衍生物
CZ20021692A CZ20021692A3 (cs) 1999-11-18 2000-11-16 Nové N-azabicykloamidové deriváty a jejich pouľití
MXPA02004911A MXPA02004911A (es) 1999-11-18 2000-11-16 Nuevo uso y nuevos derivados de n-azabiciclo-amida.
EP00981994A EP1233964B1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
US10/130,635 US6683090B1 (en) 1999-11-18 2000-11-16 N-azabicyclo-amide derivatives
HU0204245A HUP0204245A3 (en) 1999-11-18 2000-11-16 Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL14937400A IL149374A0 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
EEP200200251A EE200200251A (et) 1999-11-18 2000-11-16 Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
KR1020027006257A KR20020058014A (ko) 1999-11-18 2000-11-16 신규 용도 및 신규 ｎ-아자비시클로-아미드 유도체
JP2001538906A JP2003514818A (ja) 1999-11-18 2000-11-16 新規使用および新規ｎ−アザビシクロ−アミド誘導体
PL00355867A PL355867A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
NZ518571A NZ518571A (en) 1999-11-18 2000-11-16 New use and novel N-azabicyclo-amide derivatives
BR0015624-8A BR0015624A (pt) 1999-11-18 2000-11-16 Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
SK677-2002A SK6772002A3 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
HK02109290.6A HK1047743B (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
CA002389604A CA2389604A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives
ES00981994T ES2242653T3 (es) 1999-11-18 2000-11-16 Nuevo uso y nuevos derivados de n-azabiciclo-amida.
PT00981994T PT1233964E (pt) 1999-11-18 2000-11-16 Nova utilizacao e novos derivados de n-azabiciclo-amida
AU19073/01A AU784400B2 (en) 1999-11-18 2000-11-16 New use and novel N-azabicyclo-amide derivatives
CO00087729A CO5261607A1 (es) 1999-11-18 2000-11-17 Nuevo uso
ZA200203316A ZA200203316B (en) 1999-11-18 2002-04-25 New use and novel n-azabicyclo-amide derivatives.
BG106680A BG106680A (bg) 1999-11-18 2002-05-09 Ново приложение и нови производни на n-азабициклоамид
NO20022289A NO20022289L (no) 1999-11-18 2002-05-14 Ny anvendelse og nye N-azabisykloamidderivater
IS6385A IS6385A (is) 1999-11-18 2002-05-15 Ný notkun og nýjar N-asabísýkló-amíð afleiður

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use

Publications (1)

Publication Number Publication Date
SE9904176D0 true SE9904176D0 (sv) 1999-11-18

Family

ID=20417766

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use

Country Status (30)

Country Link
US (1) US6683090B1 (cg-RX-API-DMAC7.html)
EP (1) EP1233964B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003514818A (cg-RX-API-DMAC7.html)
KR (1) KR20020058014A (cg-RX-API-DMAC7.html)
CN (1) CN1217943C (cg-RX-API-DMAC7.html)
AR (1) AR031680A1 (cg-RX-API-DMAC7.html)
AT (1) ATE298337T1 (cg-RX-API-DMAC7.html)
AU (1) AU784400B2 (cg-RX-API-DMAC7.html)
BG (1) BG106680A (cg-RX-API-DMAC7.html)
BR (1) BR0015624A (cg-RX-API-DMAC7.html)
CA (1) CA2389604A1 (cg-RX-API-DMAC7.html)
CO (1) CO5261607A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20021692A3 (cg-RX-API-DMAC7.html)
DE (1) DE60020994T2 (cg-RX-API-DMAC7.html)
DK (1) DK1233964T3 (cg-RX-API-DMAC7.html)
EE (1) EE200200251A (cg-RX-API-DMAC7.html)
ES (1) ES2242653T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0204245A3 (cg-RX-API-DMAC7.html)
IL (1) IL149374A0 (cg-RX-API-DMAC7.html)
IS (1) IS6385A (cg-RX-API-DMAC7.html)
MX (1) MXPA02004911A (cg-RX-API-DMAC7.html)
NO (1) NO20022289L (cg-RX-API-DMAC7.html)
NZ (1) NZ518571A (cg-RX-API-DMAC7.html)
PL (1) PL355867A1 (cg-RX-API-DMAC7.html)
PT (1) PT1233964E (cg-RX-API-DMAC7.html)
SE (1) SE9904176D0 (cg-RX-API-DMAC7.html)
SK (1) SK6772002A3 (cg-RX-API-DMAC7.html)
UA (1) UA74172C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001036417A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200203316B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2002016356A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282910A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
DE60215172T2 (de) * 2001-07-06 2007-08-30 Neurosearch A/S Neue verbindungen, deren herstellung und verwendung
CA2458375A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
MXPA04003007A (es) * 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
MXPA04003986A (es) * 2001-10-26 2004-07-23 Upjohn Co Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr.
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
EP1442041A1 (en) 2001-11-08 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003210730A1 (en) 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
BR0307782A (pt) 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
NZ536197A (en) 2002-05-30 2006-08-31 Neurosearch As 3-substituted quinuclidines and their use
JP2005537297A (ja) 2002-08-01 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物
EP1531820A1 (en) 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
PL377777A1 (pl) * 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
ATE451368T1 (de) 2003-10-15 2009-12-15 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2009506037A (ja) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド ヘテロアリール置換ジアザトリシクロアルカン、その調製方法およびその使用方法
WO2007037258A1 (ja) * 2005-09-28 2007-04-05 Kumamoto University 注意欠陥・多動性障害の治療薬
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US9233106B2 (en) * 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
DE602008005928D1 (de) 2007-10-01 2011-05-12 Comentis Inc 1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
KR20100113163A (ko) 2008-02-13 2010-10-20 타가셉트 인코포레이티드 알파 ７ 니코틴 작용제 및 항정신병제의 조합
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
WO2012177856A2 (en) * 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AR101131A1 (es) 2014-07-11 2016-11-23 Comentis Inc QUINUCLIDINAS PARA LA MODULACIÓN DE ACTIVIDAD DE a7
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255467B (it) * 1992-07-29 1995-11-02 Dompe Farmaceutici Spa Ammidi acriliche farmacologicamente attive
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
HUP9901096A3 (en) * 1995-01-10 2000-12-28 Smithkline Beecham Spa Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds

Also Published As

Publication number Publication date
HUP0204245A2 (hu) 2003-03-28
IL149374A0 (en) 2002-11-10
SK6772002A3 (en) 2002-09-10
HUP0204245A3 (en) 2004-12-28
ZA200203316B (en) 2004-02-25
PT1233964E (pt) 2005-09-30
BR0015624A (pt) 2002-07-30
DE60020994T2 (de) 2006-04-27
EP1233964A1 (en) 2002-08-28
IS6385A (is) 2002-05-15
ES2242653T3 (es) 2005-11-16
ATE298337T1 (de) 2005-07-15
JP2003514818A (ja) 2003-04-22
KR20020058014A (ko) 2002-07-12
EP1233964B1 (en) 2005-06-22
DK1233964T3 (da) 2005-09-19
NO20022289D0 (no) 2002-05-14
CN1217943C (zh) 2005-09-07
CN1423651A (zh) 2003-06-11
DE60020994D1 (de) 2005-07-28
NO20022289L (no) 2002-06-24
UA74172C2 (uk) 2005-11-15
AR031680A1 (es) 2003-10-01
CA2389604A1 (en) 2001-05-25
PL355867A1 (en) 2004-05-31
AU784400B2 (en) 2006-03-23
HK1047743A1 (en) 2003-03-07
CO5261607A1 (es) 2003-03-31
MXPA02004911A (es) 2002-09-18
CZ20021692A3 (cs) 2003-01-15
US6683090B1 (en) 2004-01-27
AU1907301A (en) 2001-05-30
WO2001036417A1 (en) 2001-05-25
EE200200251A (et) 2003-06-16
BG106680A (bg) 2003-01-31
NZ518571A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
SE9904176D0 (sv) New use
CO5271691A1 (es) Nuevos compuestos
TR200102042T2 (tr) Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri.
SE9903998D0 (sv) New compounds
GB9801690D0 (en) Therapeutic agents
DE60233239D1 (de) Benzothiazepinderivate
AU2002246728A1 (en) Carboline derivatives
SE0400043D0 (sv) New compounds
SE9903997D0 (sv) New compounds
ATE346067T1 (de) Carbolinderivate
SE9803518D0 (sv) Novel compounds
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
PT992509E (pt) Novos derivados macrolidos
SE0102055D0 (sv) New Compounds
ATE170852T1 (de) Benzolsulfonamid-derivate zur behandlung der blaseninstabilität
SE9803773D0 (sv) Compounds
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
ATE330958T1 (de) Pyrazino 1&#39;2&#39;:1,6öpyrido 3,4-böindolderivate
SE0104326D0 (sv) Therapeutic heterocycles
SE0102057D0 (sv) New Salts I
SE0104333D0 (sv) Therapeutic agents
SE0102058D0 (sv) New Salts II
DE60210981D1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
DE60111553D1 (de) Hexahydropyrazino[1&#39;2&#39;:1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
SE0403118D0 (sv) New compounds 2